Welcome to our dedicated page for Mdxhealth Sa news (Ticker: MDXH), a resource for investors and traders seeking the latest updates and insights on Mdxhealth Sa stock.
MDxHealth SA reports developments in urology-focused precision diagnostics, including molecular tests used in the diagnosis and prognosis of prostate cancer and other urologic diseases. The company’s test menu is based on genomic, epigenomic, exosomal and other molecular technologies and includes products such as Confirm mdx, GPS mdx, ExoDx, Select mdx and Resolve mdx.
Recurring news for MDXH includes financial results, revenue guidance, tissue-based and liquid-based test volumes, clinical data for the Genomic Prostate Score test, and collaborations with academic prostate cancer researchers. Company updates also cover the integration of Exosome Diagnostics, earnout and warrant arrangements tied to diagnostic-test acquisitions, and corporate governance or management changes.
Summary not available.
DLA Piper represented Piper Sandler & Co. and Oppenheimer & Co. as lead book-running managers in the US$45 million IPO of MDxHealth (Nasdaq: MDXH), involving 3,750,000 American Depository Shares (ADSs) priced at US$12.00 each. The offering was structured around 37,500,000 ordinary shares, with an option for underwriters to purchase an additional 562,500 ADSs within 30 days. DLA Piper’s global capital markets team provided comprehensive advisory services for this transaction, enhancing MDxHealth's market presence.